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Abstract
Patient. A 65-year old man who had previously undergone surgery for benign prostatic hyperplasia presented with
symptoms of recurrent bladder out¯ ow obstruction. Cystoscopy revealed the presence of recurrent tissue.
Results. Histology identi® ed a leiomyosarcoma. Several years after further surgery and radiotherapy, the patient presented
with secondaries in the lungs and brain, but there was no evidence of local recurrence.
Discussion. It is suggested that combined modality therapy (conservative surgical resection followed by adjuvant radical
radiotherapy) be the initial treatment for prostatic leiomyosarcoma.
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Introduction
Leiomyosarcoma of the prostate is a rare, highly
malignant tumour, that occurs predominantly in
adults. Less than 100 cases in adults have been
published. We report another case and review the
literature. The natural history of the tumour is
characterized by rapid growth, and eventually wide
dissemination to the lungs, brain, bone and liver.
The prognosis remains poor regardless of therapy,
with all patients dying of disseminated disease
within a few years of the diagnosis. A review of the
literature over the past few decades suggests that
radical surgical treatment is the most commonly
advocated therapeutic modality. Complete excision
in most cases, however, is extremely dif® cult, com-
monly followed by recurrence, and rarely results in
cure. We suggest, for patients with localized pro-
static leiomyosarcoma, combined modality therapy
in the form of conservative prostatic surgical resec-
tion, followed by adjuvant radical radiotherapy, as
the initial treatment. Radical surgery should be re-
served only for local failure and in the absence of
distant metastasis.
Patient
A 65-year-old man presented with symptoms of
recurrent bladder out¯ ow obstruction. He had
undergone transurethral resection of the prostate 6
years previously for benign prostatic hyperplasia.
Examination revealed a benign-feeling prostatic
enlargement and cystoscopy revealed an encroach-
ment of the prostatic cavity by recurrent tissue.
Further resection was performed and histology
identi® ed a leiomyosarcoma. Further ultrasound
and CT scan for staging failed to show any evidence
of disease outside of the prostate. Radical prostatec-
tomy was advised but the patient declined. Accord-
ingly, a radical course of radiotherapy was
administered to the prostate gland after a further
deep resection of the prostate cavity.
The patient remained well for 3 years when he
presented with dyspnoea on exertion. Chest X-ray
and CT of the chest showed multiple metastases
consistent with secondaries from sarcoma of the
prostate. He received chemotherapy for palliation
but a few months later he developed a headache and
CT con® rmed secondaries in the brain. Four years
after the diagnosis, there was no evidence of local
recurrence, but the patient died of disseminated
disease in the lung and brain.
Discussion
Prostatic sarcomas are extremely rare, constituting
0.1± 0.2% of primary prostatic neoplasms. Prostatic
leiomyosarcoma (PL) is the second most common
prostatic sarcoma (after rhabdomyosarcoma) and
accounts for most cases in adults with a median age
at diagnosis of 58 years.
1 In the majority of cases,
there is no clear aetiology but previous pelvic radio-
therapy has been incriminated in some cases.
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Inkeeping with our patient, the most common pre-
senting symptoms are those of bladder neck out¯ ow
obstruction. Other symptoms include pelvic pain,
haematuria and constipation.
It is impossible to make the diagnosis of PL by
rectal examination as the ® ndings are often of a
smooth ® rm enlargement of the prostate.
In view of the rarity of PL, the diagnosis is often
unsuspected at the time of presentation, and like all
sarcomas, the importance of appropriate biopsy and
opinion of an experienced pathologist in the diag-
nosis cannot be over-emphasized.
3 Ultrasound is a
useful preliminary investigation, but CT scan or
magnetic resonance imaging are very important, not
only for evaluating the primary site but also in
determining the presence or absence of metastasis
and assessment of response to treatment.
Proper management of PL depends on sound
knowledge of its pathology, biology and natural
history, and is best achieved by close collaboration
between pathologist, urologist and oncologist. The
disease remains localized for a variable period of
time before it spreads locally to the bladder, rectum
or perineum, or to a distant location in the lungs,
brain, bone and liver, hence the importance of early
diagnosis and treatment.
PL is a highly malignant tumour for which cura-
tive therapy remains elusive. Because of its rarity, it
is not clear from the literature whether surgery,
radiotherapy, chemotherapy or a combined modal-
ity treatment offers the greatest hope. Over the last
few decades, these therapeutic modalities have been
attempted separately and in various combinations
but none resulted in cure.
4± 6 In patients with poor
survival prospects like that of PL, regardless of the
therapeutic modality, the aim of the treatment must
be to achieve and maintain local control of the
prostatic disease as long as possible with minimum
morbidity. On reviewing the literature, radical surgi-
cal excision was the most frequently and performed
therapeutic modality.
4,5 There is little evidence,
however, that it has any curative value in the man-
agement of PL. In addition, it is associated with
signi® cant physical and psychological morbidity.
Cheville et al. described 11 patients who underwent
curative radical surgery for localized PL: ® ve of
them had gross residual tumour, ® ve experienced
local recurrence 2± 41 months after surgery, and one
patient had no evidence of recurrence 4.5 months
after surgery.
4 Mottola et al. described two patients
with PL who died 13 and 20 months after radical
surgery due to recurrence.
7 Russo et al. reported a
patient with PL who died of metastatic disease soon
after radical surgery.
8 These cases are consistent
with the experience and results of other authors.
9,10
They all indicate that PL is frequently aggressive.
PL in general has a high propensity for local
recurrence and distant spread. This may be related
in part to the delay in diagnosis and presentation. In
the 1970s, the concept of using limited surgical
excision with adjuvant radical radiotherapy (com-
bined modality therapy) was introduced in the man-
agement of soft tissue sarcomas, and its value has
been demonstrated in several sites and at different
centres.
11± 13 Ahlering et al. reported the outcome of
four patients with PL treated with combined modal-
ity therapy (surgical resection and radical radiother-
apy): three of them were alive with no residual
disease at 60, 73 and 87 months follow-up.
14 Our
patient remained recurrence free for 3 years, then
died after 4 years of disseminated disease in the
lungs and brain. Locally, however, there was no
evidence of recurrence of his PL. Our experience
with this case is consistent with the experience of
others that PL is frequently aggressive but occasion-
ally it takes an indolent course.
4 The encouraging
results using conservative surgery and radical radio-
therapy (combined modality therapy) require fur-
ther national or international study of the role of
combined modality therapy in the management of
PL.
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